Anthropic is reported to have acquired Coefficient Bio, a recently founded AI-driven biotech startup with a team of less than ten people, in a transaction valued at approximately $400 million in stock. The deal centers on integrating a small, technically focused team working on AI-enabled biological research into Anthropic’s expanding life sciences effort, which spans preclinical discovery through regulatory workflows.
TechCrunch independently verified the acquisition through sources familiar with the deal, with Coefficient’s PitchBook listing also indicating a $400 million transaction. Neither Anthropic nor Coefficient has publicly confirmed the deal, though investor communications and multiple independent reports indicate it has closed.
The alleged acquisition comes just as the U.S. Department of Health and Human Services banned internal use of Anthropic’s Claude system, a decision that could have downstream implications for federal agencies, including AI-assisted drug review initiatives. At the same time, the FDA has already piloted internal tooling based on Claude, indicating uneven adoption across agencies.
Inside Coefficient Bio
Coefficient Bio has operated in stealth since its 2025 founding, with a team smaller than ten people. The company was led by CEO Aris Theologis, previously chief business officer at Evozyne and a vice president at Paragon Biosciences. At Evozyne, he established and expanded AI partnerships including one with Nvidia.
The founding team draws heavily from Genentech’s Prescient Design, the computational drug discovery unit. CTO Nathan Frey was a principal ML scientist and group leader there; co-founder Samuel Stanton, a data science PhD from NYU, was also a Prescient Design ML scientist. Joyce Hong, the fourth co-founder, was previously a principal at Roivant Sciences. Additional team members reportedly come from the same ecosystem.
Current public descriptions of Coefficient Bio’s work are limited, but reporting indicates a focus on applying artificial intelligence (AI) to improve efficiency in drug discovery and biological research.
Given the backgrounds of the founding team, the scope likely sits at the interface of protein engineering, computational biology, and model-driven experimental design, similar to approaches seen at Evozyne and related AI-native biotech platforms.
Anthropic for Life Sciences
The acquisition extends Anthropic’s recent expansion into life sciences. Over the past six months, the company has introduced domain-specific expansion for Claude for Life Sciences, and launched Claude for Healthcare, expanding its models across research, clinical operations, and regulatory processes.
Recently, Anthropic partnered with HHMI and the Allen Institute to deploy Claude-based AI agents in real-life scientific research workflows. In March, Anthropic also joined Basecamp Research, Ultima Genomics, and PacBio on the Trillion Gene Atlas, a program designed to scale biological training data from 10 billion to 1 trillion genes and connect large-scale genomic data generation to AI-driven biological design.
Eric Kauderer-Abrams, Anthropic’s head of biology and life sciences, told CNBC in October: “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding.”
If confirmed, the deal would mark a departure from Anthropic’s existing life sciences playbook of model features and research partnerships. Coefficient had no product and no revenue: this looks to be a $400M acqui-hire, priced by the scarcity of people who can work across both generative AI and drug discovery.
OpenAI isn’t lagging behind either. Just a few days before Claude for Healthcare announcement, OpenAI piloted their own ChatGPT Health/Healthcare suite. Among established collaborations with big pharma companies such as Sanofi, Moderna, and Eli Lilly, additional OpenAI work with Retro Biosciences used a protein-focused GPT-4b variant to engineer Yamanaka factors, reportedly increasing pluripotency markers more than 50-fold and improving reprogramming efficiency and cell stability. OpenAI has also backed protein engineering unicorn Chai Discovery, recently valued at $1.3B after a $130M raise.
Topic:
Industry Movers